about
Renal progenitor cells contribute to hyperplastic lesions of podocytopathies and crescentic glomerulonephritis.Systematic analysis of a novel human renal glomerulus-enriched gene expression dataset.Extracellular 3',5'-cAMP-adenosine pathway inhibits glomerular mesangial cell growth.Effects of high glucose on integrin activity and fibronectin matrix assembly by mesangial cellsNotch activation differentially regulates renal progenitors proliferation and differentiation toward the podocyte lineage in glomerular disordersUrinary CXCL1: a novel predictor of IgA nephropathy progression.Deficient degradation of homotrimeric type I collagen, α1(I)3 glomerulopathy in oim mice.Renal Lipotoxicity-Associated Inflammation and Insulin Resistance Affects Actin Cytoskeleton Organization in PodocytesARB protects podocytes from HIV-1 nephropathy independently of podocyte AT1.Protective effects of low-dose rapamycin combined with valsartan on podocytes of diabetic rats.Enhanced podocyte vesicle transport in the nephrotic rat.Adiponectin promotes functional recovery after podocyte ablation.Pathophysiology of focal segmental glomerulosclerosis.TRPC6 mutations associated with focal segmental glomerulosclerosis cause constitutive activation of NFAT-dependent transcription.Keap1 inhibition attenuates glomerulosclerosis.The novel diagnostic biomarkers for focal segmental glomerulosclerosis.Shining D' light on chronic kidney disease: mechanisms that may underpin the cardiovascular benefit of vitamin D.Renal diseases associated with hematuria in children and adolescents: a brief tutorial.mTOR inhibitors and renal allograft: Yin and Yang.Cyclosporine A--induced oxidative stress in human renal mesangial cells: a role for ERK 1/2 MAPK signaling.Is plasma renin activity a biomarker for the prediction of renal and cardiovascular outcomes in treated hypertensive patients? Observations from the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT).mTOR regulates expression of slit diaphragm proteins and cytoskeleton structure in podocytes.Sirolimus enhances cyclosporine a-induced cytotoxicity in human renal glomerular mesangial cellsLoss of the podocyte glucocorticoid receptor exacerbates proteinuria after injury.Transforming growth factor-β1/Smad3-independent epithelial-mesenchymal transition in type I collagen glomerulopathy.Proteinuria in mice expressing PKB/SGK-resistant GSK3.Morphological characterization of ckd in cats: Insights of fibrogenesis to be recognized.A novel assay to assess the effect of pharmaceutical compounds on the differentiation of podocytes.Prospects for Precision Medicine in Glomerulonephritis Treatment.Lack of association between transient receptor potential cation channel 6 polymorphisms and primary membranous glomerulonephritis.The podocyte as a direct target of immunosuppressive agents
P2860
Q33513803-38171B6C-60C2-4D80-B701-AB21E38B7E19Q33634030-E9E0CD5D-697B-4C68-AD3F-90E03D1C0450Q33890867-C30E7415-406D-4299-A6F2-E83512ADD651Q34081401-CFF2B0D2-C2BD-436D-9B35-84231F33995DQ34373905-AA34C8E2-3771-4339-8891-BE16DDB90D97Q35224820-DD5FC6B5-2B40-437E-8ABF-1EA588E23A8DQ35489554-9DB5D12F-6100-423A-B656-8620BEA537FDQ35834459-D7DEAE6B-9F8E-4E3C-AE04-14E7A927AC75Q36129864-A015B5B0-7CB0-4EAA-A4FA-565AF0A7640CQ36183003-D823763E-C109-4AF4-8333-1CBEB6C844FBQ36313502-30D0DAED-2BA7-47B2-AA63-9210C0BCB723Q36574746-02BF7F8A-0315-4F24-B426-6406D976E023Q36704678-21A58B57-BF8A-4E9E-9155-5A535FD8B909Q37139035-C496A1B3-5A0B-4F56-A30D-25E9A88C6D4AQ37668899-3CFDF014-4168-420F-8498-E500B73D2778Q37699843-D0D0B8B8-B003-4FC5-BD8B-2ADCAF61DD59Q37842680-F0A03407-CD9A-4724-9AC2-ABFFA9430A6BQ37980204-06F5EEEF-2BFB-4315-93B1-E5DEC255EDA2Q38209973-B3FB6F3D-9D77-4E8A-BE2F-80A9F3007734Q39432190-79E3F1F5-3328-4D90-9409-EB9B1CA309BFQ39559504-548287CE-1354-4BF4-9BE1-C937B50CD8C4Q39914641-79F253BD-E6CD-45CC-8A46-2AE0996E689CQ40793003-F5E19A8B-405F-46B0-A5FC-451475AAB74FQ41548278-950D55DB-D9C1-4A19-ACA2-DEC866EB2526Q41633919-572DDC8A-015B-47D2-A789-3B0E015C66A4Q46262360-0D8697FC-D13B-4EE8-97C0-5C96CDB0E238Q46287968-9E0DA313-AA6B-44BC-A06D-D70975ADC994Q48218383-623B261B-3712-4FB2-B02D-0F9820C573C0Q49300308-9AB101AD-3694-4BDB-A1FD-E93EED622701Q54424682-72ECBE4B-B3EB-4742-94CC-41BB06C0B028Q58177753-A177A1AD-A0D0-4967-872C-6616444D4470
P2860
description
2006 nî lūn-bûn
@nan
2006 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Pathogenesis of nonimmune glomerulopathies.
@ast
Pathogenesis of nonimmune glomerulopathies.
@en
Pathogenesis of nonimmune glomerulopathies.
@nl
type
label
Pathogenesis of nonimmune glomerulopathies.
@ast
Pathogenesis of nonimmune glomerulopathies.
@en
Pathogenesis of nonimmune glomerulopathies.
@nl
prefLabel
Pathogenesis of nonimmune glomerulopathies.
@ast
Pathogenesis of nonimmune glomerulopathies.
@en
Pathogenesis of nonimmune glomerulopathies.
@nl
P2093
P1476
Pathogenesis of nonimmune glomerulopathies.
@en
P2093
Christopher Kwoh
Jeffrey H Miner
M Brendan Shannon
P304
P356
10.1146/ANNUREV.PATHOL.1.110304.100119
P50
P577
2006-01-01T00:00:00Z